ERX BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates - Entered into Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease - • Appointed Tami Rachmilewitz, M.D. as Chief Medical Officer • Finalized formation of the U.S. commercial leadership team, which collectively has significant drug launch and sales experience, with particular expertise in st ...

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2022 Earnings Conference Call November 15, 2022 10:00 AM ET Company Participants John Lacey - IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Abi Vainstein-Haras - Chief Medical Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Mark Breidenbach - Oppenheimer John Vandermosten - Zacks Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2022 Results Confer ...

BioLineRx Ltd. (NASDAQ:BLRX) Q2 2022 Earnings Conference Call August 16, 2022 10:00 AM ET Company Participants Tim McCarthy - IR, LifeSci Advisors Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Abi Vainstein-Haras - Chief Medical Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Mark Breidenbach - Oppenheimer John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second ...

Exhibit 2 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position F-1 F-2 F-3 - F-4 F-5 - F-6 F-7 - F-9 | --- | |------------------------------------------------------------------| | | | | | Condensed consolidated interim statements of comprehensive | | Condensed consolidated interi ...

BioLineRx Ltd. (NASDAQ:BLRX) Q1 2022 Earnings Conference Call May 11, 2022 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - CEO Mali Zeevi - CFO Conference Call Participants Mark Breidenbach - Oppenheimer John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2022 Conference Call. All participants are presently in a listen-only mode. Following management's formal presentation instructions will be given fo ...

Call Start: 10:00 January 1, 0000 10:31 AM ET BioLineRx Ltd. (NASDAQ:BLRX) Q4 2021 Earnings Conference Call March 16, 2022 10:00 ET CompanyParticipants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer Abi Vainstein-Haras - Chief Medical Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co. John Vandermosten - Zacks Investment Research Operator Ladies and gentlemen, thank you for st ...

Exhibit 99.1 INEEX For Immediate Release BioLineRx Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - - Announced highly positive results from additional pharmacoeconomic study indirectly comparing Motixafortide plus G-CSF versus plerixafor plus G-CSF - - Cash and cash equivalents at December 31, 2021 of $57 ...

Exhibit 99.1 INEEX For Immediate Release BioLineRx Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update - Commercial assessment commissioned indicating US stem-cell mobilization opportunity of ~$360m - - Successful pre-NDA meeting with FDA; NDA submission anticipated in mid-2022 - - Announced highly positive results from additional pharmacoeconomic study indirectly comparing Motixafortide plus G-CSF versus plerixafor plus G-CSF - - Cash and cash equivalents at December 31, 2021 of $57 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) of the Securities Exchange Act of 19 ...

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2021 Earnings Conference Call November 18, 2021 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer Abi Vainstein-Haras - Chief Medical Officer Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2021 Results Confere ...